NovoCure Limited NVCR
Set alert
13.45 USD +0.24 +1.82%
As of Nov 3, 12:15 PM ET
13.21 Day range 13.56
9.82 52-week range 21.45
- YTD
- +4.02%
- 1 year
- +9.98%
- Open
- 13.30
- Prev close
- 13.21
- Mkt cap
- 1.57B
- Vol
- 325.03K
- Avg vol
- 1.44M
- EPS
- -1.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.21
- High
- 13.56
- Forward P/E
- -17.87
- Beta
- 1.08
- Short ratio
- 9.27
- Inst. own
- 90.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 15.79
- 200-d avg
- 14.82
- 1y target
- 26.43
Analyst view
Consensus: buy
Buy
Price target (mean) 26.43 +96.5% upside
Now 13.45
- Target (low)
- 17.00
- Target (mean)
- 26.43
- Target (high)
- 52.00
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.24138 | -0.31 – -0.15 | -0.22 | -9.7% | 188.98M | +8.4% | 6 |
| Next quarter | -0.21 | -0.27 – -0.11 | -0.62 | +66.1% | 188.60M | +8.4% | 4 |
| Current year | -1.05 | -1.06 – -1.03 | -1.22 | +13.9% | 739.97M | +12.9% | 4 |
| Next year | -0.77494 | -1.06 – -0.22459 | -1.05 | +26.2% | 808.29M | +9.2% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 24, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Jul 23, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 4, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 1, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 16, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Feb 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 15, 2026 | Wedbush | Reiterated | Neutral | Neutral |
| Jan 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 30, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 27, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Jul 25, 2025 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jul 8, 2025 | Ladenburg Thalmann | Initiated | — | Buy |
| Jun 27, 2025 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 23, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 16, 2025 | Wedbush | Maintained | Neutral | Neutral |
| Apr 10, 2025 | JP Morgan | Maintained | Neutral | Neutral |
| Jan 14, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 13, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 3, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 2, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 2, 2024 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| Nov 21, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 16, 2024 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Oct 1, 2024 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Jul 26, 2024 | Wells Fargo | Maintained | Overweight | Overweight |